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Abstract High lipoprotein (a) [Lp(a)] concentrations are 
an independent risk factor for cardiovascular outcomes. 
Concentrations are strongly influenced by apo(a) kringle IV 
repeat isoforms. We aimed to identify genetic loci associated 
with Lp(a) concentrations using data from five genome-wide 
association studies (n = 13,781). We identified 48 indepen-
dent SNPs in the LPA and 1 SNP in the APOE gene region to 
be significantly associated with Lp(a) concentrations. We 
also adjusted for apo(a) isoforms to identify loci affecting 
Lp(a) levels independently from them, which resulted in 31 
SNPs (30 in the LPA, 1 in the APOE gene region). Seven 
This work was supported by Austrian Science Fund Grant P 26660-B13 to C.L. 
and the “Genomics of Lipid-associated Disorders (GOLD)” of the “Austrian Ge-
nome Research Programme GEN-AU” to F.K. Other support was provided by the 
Biomedical Research Program at Weill Cornell Medicine-Qatar, funded by the Qa-
tar Foundation to N.A.Y. The NHLBI Family Heart Study was supported by Na-
tional Heart, Lung, and Blood Institute Grants U01 HL67893, U01 HL67894, 
U01 HL67895, U01 HL67896, U01 HL67897, U01 HL67898, U01 HL67899, 
U01 HL67900, U01 HL67901, and U01 HL67902. The CoLaus study was and 
is supported by research grants from GlaxoSmithKline, the Faculty of Biology and 
Medicine of Lausanne, and Swiss National Science Foundation Grants 33CSCO-
122661, 33CS30-139468, and 33CS30-148401. The KORA study was initiated 
and financed by the Helmholtz Zentrum München-German Research Center for 
Environmental Health, which is funded by the German Federal Ministry of Educa-
tion and Research (BMBF) and by the State of Bavaria. KORA research was also 
supported within the Munich Center of Health Sciences (MC-Health), Ludwig-
Maximilians-Universität, as part of LMUinnovativ. The Young Finns Study was 
financially supported by Academy of Finland Grants 286284, 134309, 126925, 
121584, 124282, 129378, 117787, and 41071; the Social Insurance Institution 
of Finland; Kuopio, Tampere, and Turku University Hospital Medical Funds 
(Grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish 
Foundation of Cardiovascular Research; Finnish Cultural Foundation; Tampere 
Tuberculosis Foundation; Emil Aaltonen Foundation; and Yrjö Jahnsson Founda-
tion. The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health.
Author’s Choice—Final version free via Creative Commons CC-BY license.
Manuscript received 10 March 2017 and in revised form 4 May 2017.
Published, JLR Papers in Press, May 16, 2017
DOI https://doi.org/10.1194/jlr.M076232
A genome-wide association meta-analysis on lipoprotein (a) 
concentrations adjusted for apolipoprotein (a) isoforms
Salome Mack,* Stefan Coassin,* Rico Rueedi,†,§ Noha A. Yousri,‡,|| Ilkka Seppälä,#  
Christian Gieger,$,**,†† Sebastian Schönherr,* Lukas Forer,* Gertraud Erhart,*  
Pedro Marques-Vidal,§§ Janina S. Ried,$ Gerard Waeber,§§ Sven Bergmann,†,§ Doreen Dähnhardt,* 
Andrea Stöckl,* Olli T. Raitakari,‡‡,|||| Mika Kähönen,## Annette Peters,**,$$,***  
Thomas Meitinger,†††,§§§,‡‡‡ Konstantin Strauch,$,|||||| KORA-Study Group, Ludmilla Kedenko,###  
Bernhard Paulweber,### Terho Lehtimäki,# Steven C. Hunt,$$$,**** Peter Vollenweider,§§  
Claudia Lamina,1,2,* and Florian Kronenberg1,2,* 
Division of Genetic Epidemiology,* Department of Medical Genetics, Molecular and Clinical Pharmacology, 
Medical University of Innsbruck, 6020 Innsbruck, Austria; Department of Computational Biology,† University 
of Lausanne, 1015 Lausanne, Switzerland; Swiss Institute of Bioinformatics,§ 1015 Lausanne, Switzerland; 
Department of Physiology and Biophysics,‡ Weill Cornell Medical College-Qatar, Doha, Qatar; Department of 
Computer and Systems Engineering,|| Alexandria University, 21526 Alexandria, Egypt; Department of Clinical 
Chemistry,# Fimlab Laboratories and University of Tampere School of Medicine, 33520 Tampere, Finland; 
Institute of Genetic Epidemiology,$ Institute of Epidemiology II,** Research Unit of Molecular 
Epidemiology,†† and Institute of Human Genetics,§§§ Helmholtz Zentrum München-German Research Center 
for Environmental Health, 85764 Neuherberg, Germany; Department of Medicine,§§ Internal Medicine, 
Lausanne University Hospital, 1015 Lausanne, Switzerland; Department of Clinical Physiology,‡‡ Turku 
University Hospital, 20520 Turku, Finland; Research Centre of Applied and Preventive Cardiovascular 
Medicine,|||| University of Turku, 20520 Turku, Finland; Department of Clinical Physiology,## Tampere 
University Hospital and University of Tampere, 33521 Tampere, Finland; German Centre for Cardiovascular 
Research (DZHK),$$ 80802 Munich, Germany; German Center for Diabetes Research (DZD e.V.),*** 85764 
Neuherberg, Germany; Institute of Human Genetics,††† Technische Universität München, 81675 München, 
Germany; Munich Cluster for Systems Neurology (SyNergy),‡‡‡ 81377 Munich, Germany; Institute of Medical 
Informatics, Biometry, and Epidemiology,|||||| Ludwig-Maximilians-Universität, 81377 Munich, Germany; First 
Department of Internal Medicine,### Paracelsus Private Medical University, 5020 Salzburg, Austria; 
Cardiovascular Genetics Division,$$$ University of Utah School of Medicine, Salt Lake City, UT 84108; and 
Department of Genetic Medicine,**** Weill Cornell Medicine, Doha, Qatar
ORCID ID: 0000-0003-2229-1120 (F.K.)
Abbreviations: CAD, coronary artery disease; CNV, copy-number-
variation; GWAS, genome-wide association study; KIV, kringle IV; LD, 
linkage disequilibrium; LDL-C, LDL cholesterol; Lp(a), lipoprotein (a); 
OR, odds ratio; OxPL, oxidized phospholipid.
1 C. Lamina and F. Kronenberg contributed equally to this work.
2 To whom correspondence should be addressed. 
e-mail: Florian.Kronenberg@i-med.ac.at (F.K.);  
Claudia.Lamina@i-med.ac.at (C.L.)
 The online version of this article (available at http://www.jlr.org) 
contains a supplement.
 Author’s Choice
 at University of Tam












Supplemental Material can be found at:
Genome-wide meta-analysis on lipoprotein (a) 1835
SNPs showed a genome-wide significant association with 
coronary artery disease (CAD) risk. A rare SNP (rs186696265; 
MAF 1%) showed the highest effect on Lp(a) and was also 
associated with increased risk of CAD (odds ratio = 1.73, 
P = 3.35 × 1030). Median Lp(a) values increased from 2.1 to 
91.1 mg/dl with increasing number of Lp(a)-increasing 
alleles. We found the APOE2-determining allele of rs7412 
to be significantly associated with Lp(a) concentrations 
(P = 3.47 × 1010). Each APOE2 allele decreased Lp(a) by 
3.34 mg/dl corresponding to 15% of the population’s 
mean values. Performing a gene-based test of association, 
including suspected Lp(a) receptors and regulators, resulted 
in one significant association of the TLR2 gene with Lp(a) 
(P = 3.4 × 104).  In summary, we identified a large number 
of independent SNPs in the LPA gene region, as well as the 
APOE2 allele, to be significantly associated with Lp(a) con-
centrations.—Mack, S., S. Coassin, R. Rueedi, N. A. Yousri, I. 
Seppälä, C. Gieger, S. Schönherr, L. Forer, G. Erhart, P. 
Marques-Vidal, J. S. Ried, G. Waeber, S. Bergmann, D. 
Dähnhardt, A. Stöckl, O. T. Raitakari, M. Kähönen, A. Peters, 
T. Meitinger, K. Strauch, KORA-Study Group, L. Kedenko, 
B. Paulweber, T. Lehtimäki, S. C. Hunt, P. Vollenweider, 
C. Lamina, and F. Kronenberg. A genome-wide association 
meta-analysis on lipoprotein (a) concentrations adjusted for 
apolipoprotein (a) isoforms. J. Lipid Res. 2017. 58: 1834–1844.
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High lipoprotein (a) [Lp(a)] concentrations have been 
shown to be an independent risk factor for CVD, as well as 
aortic valve calcification and stenosis. Mendelian random-
ization studies provided strong evidence for causality [for 
review see (1)]. Lp(a) is a lipoprotein consisting of a core 
LDL-like particle and the glycoprotein, apo(a), that are co-
valently linked to each other. It is a quantitative genetic 
trait under pronounced genetic control (1). Twin and fam-
ily studies suggest that 90–95% of variation in Lp(a) is heri-
table (2). The distribution of Lp(a) concentrations in the 
population is extremely broad, with a more than 1,000-fold 
range from below 0.1 mg/dl to more than 200 mg/dl (1, 3). 
The concentration of Lp(a) is mostly influenced by the size 
of the apo(a) isoforms, which are caused by a coding copy-
number-variation (CNV) in the LPA gene (2, 4, 5). This 
CNV contains 1 to >40 repeated plasminogen-like kringle 
IV (KIV) domains, the so-called KIV repeats, leading to a 
high heterogeneity of the apo(a) isoform distribution in 
populations. However, not all alleles are expressed (6), re-
sulting in different heterozygosity rates on the DNA level 
(up to 95% heterozygosity) and protein level (up to 70% 
heterozygosity) (1). These nonexpressed alleles are not 
uniformly distributed: shorter isoforms are more likely to 
be expressed than longer isoforms and are associated 
with higher Lp(a) concentrations (1). Lp(a) belongs to 
the strongest genetically determined risk factors for CVD, 
considering that 25–35% of the population carry short 
isoforms that are usually associated with high Lp(a) con-
centrations and a doubling of the risk for CVD. Besides the 
number of KIV-2 domains, genetic variants in the broader 
LPA gene region, as well as other variants, have been found 
to be associated with Lp(a) concentrations (1). Fifty to 
ninety percent of the overall genetic variation in Lp(a) is 
attributable to the LPA locus (1).
So far, several genome-wide association studies (GWASs) 
on Lp(a) have been published (7–14). However, these stud-
ies were limited by small sample size (7, 12, 14), restricted 
scope due to the use of a specialized cardiovascular gene-
chip (9, 10), or were conducted in certain subgroups, such 
as patients with type 2 diabetes (11), or in population iso-
lates (8, 13). All of these studies primarily identified SNPs in 
the LPA gene cluster on chromosome 6q27 (SLC22A3-
LPAL2-LPA-PLG). However, the SNPs with the highest ef-
fects were not independent from the KIV repeat (10). One 
recent GWAS in African Americans (14) also found one 
SNP in the APOE gene to be significantly associated with 
Lp(a) concentrations, which has been confirmed by a recent 
large study (15). However, Lp(a) levels and the types and 
frequencies of genetic variants, especially in the LPA gene, 
differ considerably between ethnic groups (3). Therefore, 
this finding is not generalizable to other populations.
Our project aimed to identify gene loci that are asso-
ciated with Lp(a) concentrations on a hypothesis-free 
approach using genome-wide SNP chips in studies of Euro-
pean ancestry. We included adjustment for apo(a) iso-
forms to identify loci that affect Lp(a) levels independent 
from these apo(a) isoforms. The hypothesis-free approach, 
especially, is thought to provide new avenues to genes and 
thereby research directions to find answers to unresolved 
questions regarding physiology and pathophysiology, as 
well as production and catabolism of Lp(a). Besides the 
hypothesis-free approach, we performed a gene-based test 
of association for a list of possible candidate genes consist-
ing of suspected Lp(a) receptors and regulators discussed 
in the literature. Altogether, five different primarily popu-
lation-based studies with 13,781 individuals were included 
and about 10 million SNPs analyzed.
MATERIALS AND METHODS
Study design and description of cohorts
Genome-wide analyses were performed in five different studies 
individually and were then meta-analyzed. The genome-wide sig-
nificance level was set to 5 × 108. One additional study (SAPHIR 
study) was included for an in-depth analysis of APOE genotypes. A 
detailed description of the cohorts is provided in the supplemen-
tal Materials and Methods and in supplemental Table S1. For infor-
mation on genotyping and imputation see supplemental Table S2.
Measurement of Lp(a) concentrations and apo(a) 
isoforms
For all participating studies, all Lp(a) measurements and 
apo(a) isoforms were performed by ELISA and immunoblot in 
the same laboratory (Division of Genetic Epidemiology, Inns-
bruck, Austria). Details on the measurement techniques are given 
in the supplemental Materials and Methods. A standardized 
amount of Lp(a) (150 ng) was loaded on the immunoblot. The 
predominantly expressed apo(a) isoform (in heterozygous sam-
ples), or the only band present (in homozygous samples) was used 
to adjust the statistical analysis for apo(a) isoforms. In individuals 
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showing only one band in the Western blot, the second allele was 
either not expressed (16) or they were truly homozygous, al-
though the proportion of individuals being truly homozygous on 
DNA level was expected to be lower than 5%.
Statistical methods
GWAS analysis of single studies and meta-analysis. Because the dis-
tribution of the Lp(a) concentrations were highly skewed, an in-
verse-normal transformation was applied to the measured Lp(a) 
concentrations. In each study, each SNP was tested for association 
with these inverse-normal transformed Lp(a) concentrations in an 
additive genetic model using linear regression, adjusting for age 
and sex (model 1). In addition, a second model, adjusted for age, 
sex, and the apo(a) isoform that was predominantly expressed in 
the immunoblot (model 2), was tested. To obtain interpretable ef-
fect estimates, linear regression was also performed on the original 
scale of Lp(a) for both models. Genome-wide analysis in the FamHS 
study was done using a linear mixed model accounting for familial 
dependencies described by a pedigree-based kinship matrix.
For the meta-analysis of all GWASs, the software, METASOFT 
(17), was used for all imputed SNPs that met imputation and quality 
control criteria and were present in at least two studies (9.2 M 
SNPs). Details on quality control, filtering criteria, and the meta-
analysis approach are provided in the supplemental Materials and 
Methods and supplemental Fig. S1. Gender-stratified models 
were also applied for both models, followed by a t-test on effect 
differences between men and women (18). Pairwise linkage dis-
equilibrium (LD) was evaluated using SNiPA with 1000 Genomes, 
phase1v3 data (19).
Conditional analysis. To detect independently associated 
SNPs, a conditional stepwise analysis was performed using the 
program, GCTA [version 1.24.7 (20)]. For each locus with at least 
one P value <5 × 108, the SNP with the lowest P value was taken 
as the lead SNP. It was planned to include all SNPs within a region 
±500 kb surrounding the lead SNP in the conditional analysis. 
Because genome-wide significant SNPs were also found outside of 
this range for the LPA gene region, the conditional analysis was 
extended to a range of 1.76 Mb. GCTA uses the summary statistics 
of the meta-analysis plus one reference population for LD calcula-
tion. As reference population, a combined genotype dataset of 
KORA F3 and KORA F4 was used (n = 6,002). By default, the lead 
SNP was included in the model first. Then, all SNPs in the in-
cluded gene region were tested for association in addition to the 
already included SNPs in a stepwise manner. Using all indepen-
dently associated SNPs from model 1, an unweighted, as well as 
weighted, SNP-score was derived. The unweighted SNP-score cor-
responded to the number of Lp(a)-increasing alleles. For weight-
ing,  estimates on inverse-normal transformed Lp(a) values from 
the joint model of all included SNPs were taken.
Gene-based and candidate gene analysis. In addition to the analy-
sis of single SNP effects, a gene-based scan was performed using 
meta-analysis results from both models (with and without adjust-
ing for isoforms) using the software, KGG version 3.5 (21). Gene 
regions were defined as the gene ±20 kb according to the Ref-
Gene database. Using this definition, 66.5% of all available SNPs 
were included. For the gene-based analysis, the extended Simes 
test (GATES) was used as implemented in KGG (22). To adjust 
for multiple testing, the Bonferroni method was applied on the 
number of tested genes (25,128 genes, which resulted in a signifi-
cance level of 1.99 × 106). To calculate LD between the SNPs, the 
1000G phase1v3 Reference was used. In addition to the hypothe-
sis-free gene-based test, 21 candidate genes from literature were 
tested for association (supplemental Materials and Methods) us-
ing a Bonferroni significance P value of 0.05/21 = 0.0024.
Impact of Lp(a)-associated SNPs on coronary artery disease risk. To 
assess the relevance of the identified SNPs with regard to risk on 
coronary artery disease (CAD), results from the CARDIoGRAM-
plusC4D consortium (23) were downloaded. This GWAS meta-
analysis comprises studies of mainly European, but also South 
Asian and East Asian descent, including 60,801 CAD cases and 
123,504 controls. Imputed genotypes were based on 1000 Ge-
nomes phase1v3. Log odds ratios (ORs) on CAD risk (assuming 
an additive model) and standard errors for all independently with 
Lp(a)-associated SNPs were retrieved from the summary-level 
data and matched to the minor allele.
Variance explained and heritability. The combined dataset of 
both KORA studies (n = 6,002) was used to estimate the genomic 
heritability, which is the proportion of phenotypic variance ex-
plained by all tested SNPs (24). In addition, the proportion of 
variance explained by individual SNPs was calculated with data 
from both KORA studies using the software GCTA (v.1.24.7) (20). 
In the FamHS study, the proportion of the additive (polygenic) 
variance on the phenotypic variance, the narrow-sense heritability 
h2, was estimated using GenABEL’s polygenic function, taking the 
kinship matrix into account. This narrow-sense heritability thus 
also includes the variance explained by unmeasured SNP effects 
and other factors (e.g., CNVs).
Evaluating association of APOE genotypes with Lp(a) concentra-
tions. We followed up the identified association of a SNP in the 
APOE gene (rs7412) in both KORA studies and the SAPHIR study; 
the latter was not part of the GWAS meta-analysis. Two SNPs 
(rs7412 and rs429358) unambiguously defined the apoE isoforms 
(supplemental Table S3). Because APOE E2/E2 and E4/E4 geno-
types are especially rather rare, a high imputation quality of at 
least 0.95 was required for both SNPs individually for this analysis. 
Therefore, imputed SNPs were only taken from the KORA F3 
study, whereas de novo genotyping of these two SNPs was per-
formed for KORA F4 and SAPHIR. The association analysis was 
performed for the APOE genotypes, E2/E2, E2/E3, E2/E4, E3/
E4, and E4/E4, with the most common genotype, E3/E3, as the 
reference, adjusted for age and sex and also age, sex, and apo(a) 
isoforms. All three datasets (KORA F3, KORA F4, and SAPHIR) 
were combined in one dataset and mixed effect models were per-
formed both on inverse-normal transformed Lp(a) levels and on 
the original scale of Lp(a).
Bioinformatic analysis
In order to shed some light on potential functional elements 
underlying the identified SNPs, all of our GWAS hits, as well as all 
SNPs correlated with them (r2  0.8), were investigated for: 1) 
being a coding SNP or being located at a canonical splice site; 2) 
being located in a transcription factor binding site reported by 
ENCODE (25); 3) being located in a DNase hypersensitive site 
reported by ENCODE; or 4) being located in a validated regula-
tory element reported by ORegAnno (26). GTex (27) was 
searched for reported eQTL SNPs for LPA (i.e., SNPs being cor-
related with LPA expression). Detailed methods are described in 
the supplemental Materials and Methods.
RESULTS
Description of cohorts and quality control
Supplemental Table S1 gives the descriptive characteris-
tics of all contributing studies. The P-Z-plots did not reveal 
any deviations of the reported P values and the P values 
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calculated by the  coefficient and standard error. The ge-
nomic inflation factor  ranged from 1.011 to 1.030 (sup-
plemental Table S2).
Results of meta-analysis
In both models (with and without adjusting for the pre-
dominantly expressed apo(a) isoform), SNPs in two gene 
regions were identified: LPA and APOE. Manhattan plots 
for both meta-analyses are shown in supplemental Figs. S2 
and S3 and corresponding QQ-plots in supplemental Figs. 
S4 and S5. On chromosome 6, surrounding the LPA gene, 
2,001 SNPs reached genome-wide significance in model 1, 
with the lowest P value for SNP rs55730499 (P = 3.6 × 10424, 
Fig. 1), and 1,961 SNPs reached genome-wide significance 
in model 2, with the lowest P value for SNP rs75692336 
(P = 2.90 × 10216, supplemental Fig. S6). Genome-wide 
significant SNPs for both models on chromosome 6 
were scattered over a broad region spanning 1.76 Mb 
(chr6:159,991,850-161,753,083). Additionally, in the APOE 
gene on chromosome 19, one genome-wide significant 
SNP (rs7412) was identified in model 1 (P = 3.47 × 1010, 
Fig. 2), and three genome-wide significant SNPs in model 
2 (lowest P value for SNP rs7412: 3.48 × 109; supplemental 
Fig. S7).
Further evaluation of the LPA gene region
The conditional analyses were performed for both models, 
including all SNPs in the 1.76 Mb-spanning broad LPA 
gene region. Forty-eight SNPs were independently associ-
ated with inverse-normal transformed Lp(a) in model 1 
(see supplemental Table S4 for characteristics of SNPs, 
supplemental Table S5 for results of the single studies, and 
supplemental Table S6 for results of meta-analysis). These 
SNPs were primarily located within the LPA gene, but they 
were also scattered widely in a broad region up to 1 Mb 
away from the LPA gene (Fig. 1). The effect sizes on the origi-
nal scale of Lp(a) ranged between 0.05 and 64.74 mg/dl 
per allele for the single SNPs and from 1.55 to 47.60 mg/dl 
per allele in a joint model including all 48 SNPs (median 
effect size per SNP: 5 mg/dl).
Thirty SNPs remained statistically significant after condi-
tional stepwise analysis in model 2 (see supplemental Table 
S4 for characteristics of SNPs, supplemental Table S7 for 
results of the single studies, and supplemental Table S8 for 
results of meta-analysis). Again, these SNPs were distrib-
uted over the entire broad LPA gene region, most of them 
in or close to the LPA gene. Nineteen SNPs were unique to 
this isoform-adjusted model and were not included in the 
model where we did not adjust for the apo(a) isoforms 
Fig. 1. Regional plot showing the genomic region around the LPA gene (chr6:159,991,850-161,753,083; LD refers to rs55730499, based on 
1000G EUR); P values are derived from the meta-analysis on the five cohorts including 13,781 individuals on inverse-normal transformed 
Lp(a) concentrations, adjusted for age and sex. All 48 SNPs, which are independently associated with Lp(a) in a joint model, are circled.
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(supplemental Table S4). However, three of them were in 
LD (r2 > 0.8) with SNPs from model 1 (rs140570886 in LD 
with rs1510225 from model 1 and rs3798220; rs55730499 
in LD with rs118039278 from model 1 and rs10466872; 
rs59614420 in LD with rs4252109 from model 1). There-
fore, 16 SNPs, which were identified in model 1, were as-
sociated with Lp(a) independently from isoforms and 
other Lp(a)-associated SNPs.
Both weighted and unweighted SNP-scores were derived 
from all 48 SNPs in the conditional model 1. Figure 3 shows 
that median values of Lp(a) increased from 2.1 mg/dl for 
individuals with the minimum number of Lp(a)-increasing 
alleles to 91.1 mg/dl for individuals with the maximum 
number of Lp(a)-increasing alleles. A linear increase was 
observed, but in the medium range of the risk score many 
outliers were located at the upper tail of the Lp(a) distribu-
tion. This might be due to the skewed distribution of 
Lp(a) concentrations and the very wide range of the singu-
lar SNP effects (see above). Nevertheless, the weighted 
SNP-score explained 36% of the phenotypic variance of 
Lp(a) concentrations.
Evaluation of potential functional or regulatory impact
We first investigated to determine whether the marker 
SNP or any of its proxies were known coding variants 
(supplemental Tables S4, S9). This resulted in 12 SNPs be-
ing located in exons, 6 thereof being missense variants and 
6 being synonymous variants. Interestingly, all six missense 
variants were located in LPA, while only one of the six syn-
onymous variants was located in LPA. The rs41272110 
(LPA KIV-8), rs41259144 (LPA KIV-4), and rs41267807 
(LPA, protease domain) were concordantly reported as be-
ing damaging by Polyphen (28) and SIFT (29), whereas 
the well-known LPA SNP, rs3798220, was classified as be-
nign by SIFT, but as “possibly damaging” by Polyphen. The 
two remaining missense SNPs, rs4252125 in PLG and 
rs41267809 in LPA, were concordantly predicted to be be-
nign. The previously described SNP, rs41272114, is located 
on a splice site and causes null alleles (30–32). Other 
known nonsense variants are too rare (33) to be detected 
by GWASs or occur in different ethnicities (34).
However, additional in silico evaluation of these SNPs 
was hampered by the fact that GTEx, the largest eQTL re-
source available so far, does not yet report eQTL data for 
LPA in liver tissue, while LPA expression is tightly regulated 
and happens nearly exclusively in liver tissue.
Further evaluation of the APOE gene region
Conditional analyses, including SNPs from the APOE 
region (lead SNP ±500 kb: chr19: 44,912,079-45,912,079) 
Fig. 2. Regional plot showing the genomic region defined by the APOE lead SNP, rs7412, ±500 kb (LD refers to rs7412, based on 1000G 
EUR); P values are derived from the meta-analysis on the five cohorts on inverse-normal transformed Lp(a) concentrations, adjusted for age 
and sex.
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yielded no additional genome-wide significant SNPs after 
adjusting for the top SNP (rs7412). This SNP defined the 
APOE2 allele and explained 0.5% of the phenotypic variance 
of inverse-normal transformed Lp(a) levels. Each APOE2 
copy decreased Lp(a) concentrations by 3.34 mg/dl corre-
sponding to 15% of the population’s mean values (supple-
mental Table S6). An extended evaluation of APOE genotypes 
was performed using data from the KORA F3, KORA F4, 
and the SAPHIR studies combined. The E2/E2 genotype 
was associated with a decrease of Lp(a) by 10.5 mg/dl com-
pared with the E3/E3 genotype (P = 7.77 × 105), while the 
effect was about half as high (4.7 mg/dl) for E2/E3 (P = 
1.05 × 108) and E2/E4 (P = 0.0191), indicating a rather 
additive effect of the E2 allele (Fig. 4). Conversely, E4/E4 
was associated with a nonsignificant increase of Lp(a). Fur-
ther adjusting for apo(a) isoforms only attenuated the ef-
fect estimates for E4/E4, but did not change the effect 
estimates and/or P values for the other APOE genotypes.
Gender-stratified analyses
GWASs stratified for gender did not result in any addi-
tional genome-wide significant hits outside the wider LPA 
and APOE gene region, neither for men, nor for women. 
There was also no genome-wide significant SNP-gender in-
teraction effect for both adjustment models.
Genome-wide variance explained and heritability
The genome-wide SNP-based explained variance, including 
the entire dataset of available SNPs (genomic heritability), 
was estimated to be 49.3% in both KORA studies [95% CI: 
(32.0%; 66.5%)]. A narrow-sense heritability h2 of Lp(a) 
was calculated to be 91.7% from the polygenic model in the 
family-based FamHS study. This estimate included not only 
the measured SNP effects, but also unmeasured factors.
Gene-based and candidate gene analyses
The genome-wide gene-based association scan resulted 
in 23 significant genes for the inverse-normal transformed 
Lp(a) concentrations in model 1 and in 20 significant 
genes in model 2. All of them were located either in the 
broad LPA or APOE gene region (supplemental Table S10).
The gene-based test of association for a list of possible 
candidate genes consisting of suspected Lp(a) receptors 
and regulators discussed in the literature resulted in one 
significant association of the TLR2 gene with Lp(a) for 
model 1 (P = 3.4 × 104; supplemental Table S11). No sig-
nificant association within the candidate genes was found 
for model 2 (supplemental Table S11).
Impact of Lp(a)-associated SNPs on CAD risk
From all 49 genetic variants that were shown to be inde-
pendently associated with Lp(a) in model 1 (48 in the LPA 
gene region plus rs7412 in APOE), 40 were present in sum-
mary-level data retrieved from the CARDIoGRAMplusC4D 
consortium. Nine low-frequency variants (MAF <1%) were 
missing. Figure 5 shows how the effect estimates on Lp(a) 
relate to the ORs for CAD risk. Seven SNPs were even sig-
nificantly associated with CAD on a genome-wide scale (P < 
5 × 108). The highest effect was for rs186696265, which 
showed an OR of 1.73 (P = 3.35 × 1030) with CAD risk for 
each copy of the minor allele (supplemental Table S13).
DISCUSSION
The meta-analysis of five different studies revealed SNPs 
in two genomic regions to be significantly associated with 
Lp(a) concentrations. Within a broad region surrounding 
the LPA gene, about 2,000 genome-wide significant SNPs 
were identified, of which 48 were still genome-wide signifi-
cant in a joint model after stepwise conditional analysis. 
The apo(a) isoforms determined via Western blot were avail-
able for all 13,781 participants included in the meta-analysis. 
To our knowledge, this is the largest GWAS meta-analysis 
on Lp(a) concentrations adjusting for apo(a) isoforms. 
Adjusting for apo(a) isoforms resulted in 30 independently 
Fig. 3. Boxplot of Lp(a) concentration for groups of 
a SNP-score [sum of Lp(a)-increasing alleles] derived 
from the 48 independent SNPs in the broad LPA gene 
region. An underlying bar plot shows the distribution 
of the score in KORA F3 and KORA F4. The blue line 
indicates the predicted values of Lp(a) for mid-inter-
val values of the SNP-score, based on a linear regres-
sion from the SNP-score on Lp(a).
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associated SNPs in the broad LPA gene region, most of 
them different from the SNPs found in the previous model. 
In addition, we found that carriers of the APOE2 allele of 
the APOE locus had significantly lower Lp(a) levels com-
pared with APOE E3/E3 genotypes. The clinical impact of 
the SNPs found to be associated with Lp(a) concentrations 
was underscored by the observation that seven SNPs were 
even significantly associated with CAD on a genome-wide 
scale in the CARDIoGRAMplusC4D consortium.
Findings in the LPA gene region
The largest contributor of Lp(a) concentration variability 
was the number of the KIV repeats in the LPA gene. Fur-
thermore, several SNPs in the LPA gene region were found 
to be associated with Lp(a) concentrations. For many of the 
associations, it was not clear whether they causally regulate 
Lp(a) concentrations, as discussed recently (1). However, 
the leading SNPs in GWASs on Lp(a) have not been such 
functional SNPs anyway, but rather SNPs correlated with 
KIV repeats. Two SNPs have been repeatedly reported 
and are already well-established: rs10455872 and rs3798220 
(9–11, 13). Both SNPs have been found to partially tag short 
apo(a) isoforms with 17–20 and 19–21 repeats, respectively. 
Therefore, carriers of the minor alleles of these two SNPs 
have higher Lp(a) levels and consequently higher risk of 
developing coronary disease (10). However, only about half 
of the short high-risk apo(a) isoforms are tagged by these 
two SNPs (35). Moreover, rs3798220 has been reported to 
be associated with increased oxidized phospholipid (OxPL) 
carriage on apoB-100 (36, 37).
The 48 SNPs that remained significant after applying a 
stepwise conditional model can be seen as rather indepen-
dent from each other and explain 36% of the variance in 
Lp(a) concentrations. The lead SNP, which was selected in 
the conditional analysis (rs118039278) was in perfect LD 
(r2 = 1) with the well-known KIV-tagging SNP, rs10455872 
(P = 9.7 × 10418). The other KIV-tagging SNP, rs3798220, 
was not included in the 48 SNP-score, but was captured by 
another SNP in perfect LD (rs1510224). Three out of the 
48 SNPs have already been described in the literature: 
rs7770628 has been found to be associated with Lp(a) con-
centrations greater than 14 mg/dl (7); rs41272114 causes 
a splicing defect and results in a null-allele (38), and 
rs186696265 has been identified in two recent GWAS 
meta-analyses on lipid-traits aiming to identify specifically 
rare variants in already known lipid loci (39, 40). The SNP, 
rs186696265, had a MAF of 1.1% (1000G phase1v3) and 
was shown to be associated with LDL cholesterol (LDL-C) 
and total cholesterol, but only in Europeans. In our analy-
sis, this SNP had the highest effect size on Lp(a) concen-
trations; each copy of the minor allele of this SNP increased 
Lp(a) levels by 65 mg/dl, or by 48 mg/dl in a joint model 
after adjustment for all of the 47 other independent SNPs. 
As Lp(a) particles contain roughly 30% cholesterol (41) 
that is included in each common cholesterol measure-
ment method, the recently found association of this SNP 
with LDL-C and total cholesterol (39, 40) might be ex-
plained by the effect of this SNP on Lp(a) concentrations. 
An Lp(a)-increasing effect of 65 mg/dl would translate 
into an increase of LDL-C of 20 mg/dl. Of note, this SNP 
Fig. 4. Results of a mixed model (using data from KORA F3, KORA F4, and SAPHIR combined) evaluating the effects from APOE geno-
types, defined as described in supplemental Table S3, on untransformed Lp(a) values in milligrams per deciliter (A), as well as on inverse-
normal transformed Lp(a) (B). Both panels show  estimates and 95% CI for age- and sex-adjusted models (in black), as well as age-, sex-, 
and isoform-adjusted models (in blue). P values are derived from the model using inverse-normal transformed Lp(a).
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is located between two intergenic enhancer regions, which 
have been proposed to regulate LPA expression (42) (sup-
plemental Fig. S8) and is in partial LD (r2 = 0.69, D′ = 0.95) 
with a SNP within the putative regulatory enhancer re-
gion, DHIII (rs7758766) (43). This SNP also shows a 
partial LD (r2 = 0.64) with rs3798220, described by Clarke 
et al. (10).
To detect SNPs whose effects did not merely reflect LD 
with the KIV repeat, we used models additionally adjusting 
for apo(a) isoforms. Former studies looking at correlations 
of SNPs in the LPA gene region with KIV repeats or isoform 
size led to inconsistent results: one study found no cor-
relation of SNPs with KIV repeats (44), while others 
concordantly found a high correlation of one specific SNP 
(rs10455872) with KIV copy number and short isoform 
(10, 45). The largest GWAS up to now that adjusted for 
apo(a) isoforms was performed in 1,376 Old Order Amish 
(13). However, only SNPs on chromosome 6q25-26 were 
adjusted for isoforms, which resulted in a modest reduc-
tion of the strength of the SNPs in this region with the 
Lp(a) cholesterol levels. As the published results are het-
erogeneous, we concluded that a systematic adjustment for 
the apo(a) isoforms on a large scale was needed to: 1) dis-
entangle the influence of partially correlated variants on 
Lp(a) levels with the LPA gene region; and 2) increase 
power for detecting other genes that have an influence on 
Lp(a) levels. However, adjusting for apo(a) isoforms is not 
straightforward. The analysis of isoforms on the protein 
level by Western blot provides allele-specific isoform sizes. 
Because not all apo(a) isoforms are expressed, the detected 
apo(a) isoforms do not fully reflect the alleles on the DNA 
level. Furthermore, even if both isoforms can be detected, 
one of them, usually the shorter one, might be predomi-
nating in plasma. From several different statistical model-
ing strategies, the predominantly expressed apo(a) isoform 
explains the highest variability of Lp(a) and is, in our view, 
the best way to account for apo(a) isoforms in statistical 
models. Still, the contribution of the second isoform is 
ignored and therefore, adjusting for the predominantly 
expressed apo(a) isoform can only partly remove the asso-
ciation with SNPs that is just due to LD with KIV repeats.
Consequently, known KIV-tagging SNPs (rs10455872, 
rs3798220) were still highly significantly associated with 
Lp(a) concentrations after adjusting for apo(a) isoforms, 
but the association was attenuated massively. In this iso-
form-adjusted model, a set of 30 SNPs independently 
associated with Lp(a) was identified by using a stepwise 
conditional model, 16 of them unique and not corre-
lated with any SNP contained in model 1. The top-hit 
(rs75692336) represented a cluster of correlated SNPs 
spanning over the LPA gene, the intergenic region be-
tween LPA and PLG, and the PLG gene. It was highly cor-
related with the missense variant, rs41272110, in KIV-8 
[r2 = 0.87; also known as T23P (30) or T12P (46)], which 
was predicted to be deleterious to the protein function and 
has been associated with reduced Lp(a) levels before (30, 
46). Moreover, we recently found rs75692336 to tag a fre-
quent splice-site variant within the KIV-2 repeat, that ex-
plains 20% of the Lp(a) variance in low molecular weight 
isoform carriers (47). This splice-site variant was discov-
ered by means of a next generation ultra-deep sequencing 
approach, which aimed to explain Lp(a) values that were 
discordant to what one would expect from the respective 
apo(a) isoforms. In the same manner, our isoform-adjustment 
approach seemed to find not only isoform-independent 
SNPs, but particularly SNPs leading to Lp(a) values that 
deviated from what would be expected given the observed 
isoform. As in the first model, the highest effect size on 
Lp(a) concentrations was found for SNP rs186696265, 
located near the known intergenic enhancer regions 
(supplemental Fig. S8). Two out of the 16 unique and 
independently associated SNPs were already described in 
the literature. The SNP, rs3798221, was already found to be 
associated with Lp(a) levels (10), MI (48), Lp(a) levels in 
women (49), and was found to be associated with Lp(a) 
concentration and marginally associated with KIV copy 
number in three ethnicities (South Asians, Chinese, and 
European Caucasians) (45). The SNP, rs56393506, was al-
ready found the be associated with Lp(a) levels (50). Be-
cause these 16 independent SNPs were only identified by 
adjusting for the apo(a) isoform, they might exert an effect 
on Lp(a) and, as a result, on CAD risk only in subgroups of 
Fig. 5. Scatterplot showing the effect estimates on 
inverse normally transformed Lp(a) levels (±95% CI) 
on the x axis and the ORs for CAD risk (±95% CI) on 
the y axis (derived from theCARDIoGRAMplusC4D 
consortium) for all 40 SNPs, which were identified in 
model 1 (age- and sex-adjusted) and which were avail-
able in the CARDIoGRAMplusC4D results. All SNPs, 
which are also genome-wide significantly associated 
with CAD risk, are marked in green.
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isoforms (e.g., only in low or high molecular weight iso-
forms), which should be subject to further research.
Association with APOE
Previous studies evaluating the association of variants in 
the APOE gene with Lp(a) were mostly non-GWASs and 
produced inconsistent results (supplemental Table S12). 
While some reported no contribution of APOE to Lp(a) 
variation, others showed an Lp(a)-lowering effect of APOE2 
compared with APOE3, partially in a context-dependent 
manner, e.g., in women or apo(a) isoform dependent. We 
clearly show that the Lp(a)-lowering effect of APOE2 did 
not depend on either gender or apo(a) isoform size.
apoE is part of chylomicrons, remnants, and VLDL, IDL, 
and HDL particles and mediates removal of remnants from 
circulation via LDLR, LRP1, and HSPG receptors (51). 
apoE has also been reported in a triglyceride-rich subspe-
cies of circulating Lp(a) particles (52). Two missense SNPs 
(rs7412, rs429358) define three isoforms named E2, E3, 
and E4, the two mutant isoforms E2 and E4 presenting 
markedly different physiological functions (51). E2 pres-
ents only 1% of the LDLR binding affinity compared 
with E3 and E4 (51) and results in impaired removal of 
VLDL particles (53). Coincidence of homozygous APOE2 
and conditions causing high VLDL, such as obesity, led to 
hyperlipoproteinemia type III (54).
The observation that APOE2 was associated with lower 
Lp(a) levels confirms previous reports (15, 55), albeit the 
mechanism has not been elucidated yet. Effects of the APOE 
genotype on both Lp(a) catabolism and synthesis have 
been proposed (15). Assuming a competition of LDL-C, 
Lp(a), and apoE-carrying triglyceride-rich lipoproteins for 
common receptors, it has been suggested recently that 
Lp(a) concentrations are decreased in APOE2 carriers be-
cause the decreased receptor affinity of apoE2 increases 
the number of receptors available for LDL-C and Lp(a) 
(15). On the other hand, an effect on synthesis rate is 
also conceivable. APOE genotypes exert several secondary 
effects on lipoprotein metabolism by altering the hepatic 
lipoprotein remnant metabolism (55). Given that Lp(a) 
is synthesized by the liver (3) and synthesis rate represents 
the main determinant of Lp(a) levels (56), APOE2 may thus 
affect the availability of substrate for Lp(a) formation (55).
Gene-based candidate gene analyses
To investigate minor effects not captured by a single-
SNP analysis, we performed a gene-based analysis for candi-
date genes that were reported to bind Lp(a) and/or 
regulate LPA or PCSK9. Finally, only TLR2 showed a signifi-
cant association with Lp(a) levels. TLR2 has been shown to 
concur with CD36 and TLR6 in Lp(a)-transported OxPL 
(57). However, to our knowledge, the reverse effect of an 
influence of TLR2 on Lp(a) levels has not been shown yet. 
Because neither scavenger receptor CD36, which internal-
izes OxPL, nor TLR6, which dimerizes with TLR2 in OxPL 
recognition (57), were significant in our analysis; the bio-
logical basis of this association might instead reside in the 
other manifold roles of TLR2 in innate immunity and inflam-
mation (58). Acute phase reactions have been proposed to 
affect Lp(a) levels, albeit the magnitude and direction re-
mains controversial (1). Furthermore, in mice, TLR2 acti-
vation was also shown to result in a 14-fold increase in 
PCSK9 expression (59), another known regulator of Lp(a) 
in humans. Thus various potential routes of action of TLR2 
on Lp(a) levels exist, although strict replication and fur-
ther studies will be needed to elucidate the mechanism of 
this finding.
Heritability and explained variance of Lp(a) 
concentrations
The genome-wide-SNP-based explained variance, in-
cluding the entire dataset of available SNPs (genomic heri-
tability), was estimated to be 49.3% in both KORA studies. 
In contrast, the narrow-sense heritability h2 of Lp(a) de-
rived from the polygenic model in the family-based FamHS 
study, was estimated to be 91.7%. The genomic heritability 
only includes the measured SNP effects. The narrow-sense 
heritability also includes unmeasured SNP effects, CNVs, 
and other genetic effects. A major reason for the big differ-
ence between these two heritability estimates is most prob-
ably due to the KIV repeats, which are only partly covered 
by LD with the measured SNP effects.
The weighted SNP-score that was derived based on the 
48 independently associated SNPs from model 1 explained 
36% of the phenotypic variance of Lp(a) concentrations. 
As two SNPs of the SNP-score (rs118039278 and rs1510224) 
were in perfect LD with the SNPs, rs10455872 and rs3798220, 
partially tagging KIV, this estimate of explained variance 
might also be influenced by effects from the KIV repeats 
and not solely from the SNPs themselves. These two SNPs, 
which are usually taken as genetic instruments to predict 
Lp(a), jointly explain roughly 20% of the phenotypic vari-
ance of Lp(a) in the KORA studies we used for our meta-
analyses. Therefore, we would expect an improvement in 
accuracy in analyses containing a SNP score when taking 
the 48 SNPs instead of taking rs10455872 and rs3798220 
only.
Impact of Lp(a)-associated SNPs on CAD risk
We observed a direct proportional relationship of 
Lp(a)-associated variants with CAD risk increase for Lp(a)-
increasing variants and a decrease in risk for Lp(a)-decreasing 
variants. This is in line with several previous studies, which 
were performed primarily on the highly cited variants, 
rs10455872, rs3798220, and rs41272114 (10, 60, 61). In pre-
vious studies that evaluated the causal relationship of Lp(a) 
with CAD, rs10455872 and rs3798220, especially, have been 
used as instrumental variables to determine the “geneti-
cally regulated” proportion of Lp(a). Although both SNPs 
are not included in our identified SNP set, they are re-
placed by other variants (rs118039278 and rs3798220) in 
perfect LD, which are associated with an OR for CAD risk 
of 1.36 and 1.40, respectively. We could also show that the 
SNP, rs186696265, which presents the highest effect size 
on Lp(a) in our investigation, also presents the highest OR 
for CAD of all investigated SNPs (OR = 1.73) in the LPA gene 
region. Therefore, with respect to CAD risk, rs186696265 
seems to be at least equivalent or even superior to the 
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well-known SNPs. Because this SNP is rather rare, it has not 
been detected before.
The exact functional effects of the SNPs annotated in 
Fig. 5 on CAD risk are still unknown and might reside both 
in the regulation of Lp(a) levels or, in the case of the 
rs3798220-tagging SNP, rs1510224, in modification of 
OxPL carriage on apoB100 (36). It is also remarkable that 
only one SNP seems to deviate from the linear relationship 
between effect sizes on Lp(a) and the log ORs for CAD 
risk, which is rs7412. Because rs7412 in the APOE gene is 
also associated with a decrease in LDL-C, independently 
from its association on Lp(a), the effect on CAD risk is not 
only due to Lp(a), but also might be triggered by a reduc-
tion in LDL-C.
Altogether, our findings add to the growing evidence 
that lowering Lp(a) levels might be a valuable strategy to 
reduce the risk of CAD (61). This is even more important 
in the light of emerging therapies, such as PCSK9-inhibitors 
or specific oligonucleotide therapies, that are able to lower 
Lp(a) levels by up to 30% and 90%, respectively (62, 63).
CONCLUSIONS
This GWAS meta-analysis in 13,781 participants from five 
different cohorts revealed up to 48 independent SNPs in 
the broad LPA gene region that are associated with Lp(a). 
One rather rare variant, which was shown to be associated 
with Lp(a) independently from apo(a) isoforms, was asso-
ciated with the highest effect size on Lp(a) of all investi-
gated SNPs and likewise also with the highest CAD risk. 
This investigation also provided evidence of the involve-
ment of the apoE2 isoform, as well as the TLR2 gene, in the 
regulation of Lp(a) concentrations.
The KORA-Study Group consists of A. Peters (speaker), J. 
Heinrich, R. Holle, R. Leidl, C. Meisinger, K. Strauch, and their 
co-workers, who are responsible for the design and conduct of 
the KORA studies. Data on CAD/myocardial infarction were 
contributed by CARDIoGRAMplusC4D investigators and were 
downloaded (www.CARDIOGRAMPLUSC4D.ORG).
REFERENCES
 1. Schmidt, K., A. Noureen, F. Kronenberg, and G. Utermann. 2016. 
Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 57: 
1339–1359.
 2. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. 
H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 
90% of the variation in plasma lipoprotein(a) concentrations. J. 
Clin. Invest. 90: 52–60.
 3. Kronenberg, F., and G. Utermann. 2013. Lipoprotein(a): resur-
rected by genetics. J. Intern. Med. 273: 6–30.
 4. Kraft, H. G., S. Köchl, H. J. Menzel, C. Sandholzer, and G. Utermann. 
1992. The apolipoprotein (a) gene: a transcribed hypervariable lo-
cus controlling plasma lipoprotein (a) concentration. Hum. Genet. 
90: 220–230.
 5. Lackner, C., E. Boerwinkle, C. C. Leffert, T. Rahmig, and H. H. 
Hobbs. 1991. Molecular basis of apolipoprotein (a) isoform size 
heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. 
Invest. 87: 2153–2161.
 6. Kraft, H. G., A. Lingenhel, R. W. Pang, R. Delport, M. Trommsdorff, 
H. Vermaak, E. D. Janus, and G. Utermann. 1996. Frequency 
distributions of apolipoprotein(a) kringle IV repeat alleles and 
their effects on lipoprotein(a) levels in Caucasian, Asian, and 
African populations: the distribution of null alleles is non-random. 
Eur. J. Hum. Genet. 4: 74–87.
 7. Melzer, D., J. R. B. Perry, D. Hernandez, A-M. Corsi, K. Stevens, I. 
Rafferty, F. Lauretani, A. Murray, J. R. Gibbs, G. Paolisso, et al. 2008. 
A genome-wide association study identifies protein quantitative trait 
loci (pQTLs). PLoS Genet. 4: e1000072.
 8. Ober, C., A. S. Nord, E. E. Thompson, L. Pan, Z. Tan, D. 
Cusanovich, Y. Sun, R. Nicolae, C. Edelstein, D. H. Schneider, 
et al. 2009. Genome-wide association study of plasma lipoprotein(a) 
levels identifies multiple genes on chromosome 6q. J. Lipid Res. 50: 
798–806.
 9. Zabaneh, D., M. Kumari, M. Sandhu, N. Wareham, N. Wainwright, 
T. Papamarkou, J. Hopewell, R. Clarke, K. Li, J. Palmen, et al. 2011. 
Meta analysis of candidate gene variants outside the LPA locus with 
Lp(a) plasma levels in 14,500 participants of six White European 
cohorts. Atherosclerosis. 217: 447–451.
 10. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. 
C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al.; 
PROCARDIS Consortium. 2009. Genetic variants associated with 
Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 
2518–2528.
 11. Qi, Q., T. Workalemahu, C. Zhang, F. B. Hu, and L. Qi. 2012. 
Genetic variants, plasma lipoprotein(a) levels, and risk of cardio-
vascular morbidity and mortality among two prospective cohorts of 
type 2 diabetes. Eur. Heart J. 33: 325–334.
 12. Kivimäki, M., C. G. Magnussen, M. Juonala, M. Kähönen, J. 
Kettunen, B-M. Loo, T. Lehtimäki, J. Viikari, and O. T. Raitakari. 
2011. Conventional and Mendelian randomization analyses suggest 
no association between lipoprotein(a) and early atherosclerosis: the 
Young Finns Study. Int. J. Epidemiol. 40: 470–478.
 13. Lu, W., Y-C. Cheng, K. Chen, H. Wang, G. S. Gerhard, C. D. Still, 
X. Chu, R. Yang, A. Parihar, J. R. O’Connell, et al. 2015. Evidence 
for several independent genetic variants affecting lipoprotein (a) 
cholesterol levels. Hum. Mol. Genet. 24: 2390–2400.
 14. Li, J., L. A. Lange, J. Sabourin, Q. Duan, W. Valdar, M. S. Willis, 
Y. Li, J. G. Wilson, and E. M. Lange. 2015. Genome- and exome-
wide association study of serum lipoprotein (a) in the Jackson Heart 
Study. J. Hum. Genet. 60: 755–761.
 15. Moriarty, P. M., S. A. Varvel, P. L. S. M. Gordts, J. P. McConnell, 
and S. Tsimikas. 2017. Lipoprotein(a) mass levels increase signifi-
cantly according to APOE genotype: an analysis of 431 239 patients. 
Arterioscler. Thromb. Vasc. Biol. 37: 580–588.
 16. Utermann, G., H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, 
and C. Seitz. 1987. Lp(a) glycoprotein phenotypes. Inheritance 
and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. 
Invest. 80: 458–465.
 17. Han, B., and E. Eskin. 2011. Random-effects model aimed at dis-
covering associations in meta-analysis of genome-wide association 
studies. Am. J. Hum. Genet. 88: 586–598.
 18. Behrens, G., T. W. Winkler, M. Gorski, M. F. Leitzmann, and I. M. 
Heid. 2011. To stratify or not to stratify: power considerations for 
population-based genome-wide association studies of quantitative 
traits. Genet. Epidemiol. 35: 867–879.
 19. Arnold, M., J. Raffler, A. Pfeufer, K. Suhre, and G. Kastenmüller. 
2015. SNiPA: an interactive, genetic variant-centered annotation 
browser. Bioinformatics. 31: 1334–1336.
 20. Yang, J., S. H. Lee, M. E. Goddard, and P. M. Visscher. 2011. GCTA: 
a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88: 
76–82.
 21. Li, M-X., P. C. Sham, S. S. Cherny, and Y-Q. Song. 2010. A knowl-
edge-based weighting framework to boost the power of genome-
wide association studies. PLoS One. 5: e14480.
 22. Li, M-X., H-S. Gui, J. S. H. Kwan, and P. C. Sham. 2011. GATES: 
a rapid and powerful gene-based association test using extended 
Simes procedure. Am. J. Hum. Genet. 88: 283–293.
 23. Nikpay, M., A. Goel, H-H. Won, L. M. Hall, C. Willenborg, S. 
Kanoni, D. Saleheen, T. Kyriakou, C. P. Nelson, J. C. Hopewell, 
et al. 2015. A comprehensive 1,000 Genomes-based genome-wide 
association meta-analysis of coronary artery disease. Nat. Genet. 47: 
1121–1130.
 24. de Los Campos, G., D. Sorensen, and D. Gianola. 2015. Genomic 
heritability: what is it? PLoS Genet. 11: e1005048.
 25. Birney, E., J. A. Stamatoyannopoulos, A. Dutta, R. Guigó, T. R. 
Gingeras, E. H. Margulies, Z. Weng, M. Snyder, E. T. Dermitzakis, 
R. E. Thurman, et al. 2007. Identification and analysis of functional 
 at University of Tam












Supplemental Material can be found at:
1844 Journal of Lipid Research Volume 58, 2017
elements in 1% of the human genome by the ENCODE pilot proj-
ect. Nature. 447: 799–816.
 26. Lesurf, R., K. C. Cotto, G. Wang, M. Griffith, K. Kasaian, S. J. M. 
Jones, S. B. Montgomery, and O. L. Griffith; Open Regulatory 
Annotation Consortium. 2016. ORegAnno 3.0: a community-driven 
resource for curated regulatory annotation. Nucleic Acids Res. 44: 
D126–D132.
 27. GTEx Consortium. 2015. Human genomics. The Genotype-Tissue 
Expression (GTEx) pilot analysis: multitissue gene regulation in hu-
mans. Science. 348: 648–660.
 28. Adzhubei, I. A., S. Schmidt, L. Peshkin, V. E. Ramensky, A. 
Gerasimova, P. Bork, A. S. Kondrashov, and S. R. Sunyaev. 2010. 
A method and server for predicting damaging missense mutations. 
Nat. Methods. 7: 248–249.
 29. Kumar, P., S. Henikoff, and P. C. Ng. 2009. Predicting the effects 
of coding non-synonymous variants on protein function using the 
SIFT algorithm. Nat. Protoc. 4: 1073–1081.
 30. Ogorelkova, M., H. G. Kraft, C. Ehnholm, and G. Utermann. 2001. 
Single nucleotide polymorphisms in exons of the apo(a) kringle IV 
types 6 to 10 domain affect Lp(a) plasma concentrations and have 
different patterns in Africans and Caucasians. Hum. Mol. Genet. 10: 
815–824.
 31. Kyriakou, T., U. Seedorf, A. Goel, J. C. Hopewell, R. Clarke, H. 
Watkins, and M. Farrall; PROCARDIS Consortium. 2014. A com-
mon LPA null allele associates with lower lipoprotein(a) levels 
and coronary artery disease risk. Arterioscler. Thromb. Vasc. Biol. 34: 
2095–2099.
 32. Lim, E. T., P. Würtz, A. S. Havulinna, P. Palta, T. Tukiainen, K. 
Rehnström, T. Esko, R. Mägi, M. Inouye, T. Lappalainen, et al. 
2014. Distribution and medical impact of loss-of-function variants in 
the Finnish founder population. PLoS Genet. 10: e1004494.
 33. Parson, W., H. G. Kraft, H. Niederstätter, A. W. Lingenhel, S. Köchl, 
F. Fresser, and G. Utermann. 2004. A common nonsense mutation 
in the repetitive kringle IV-2 domain of human apolipoprotein(a) 
results in a truncated protein and low plasma Lp(a). Hum. Mutat. 
24: 474–480.
 34. Noureen, A., F. Fresser, G. Utermann, and K. Schmidt. 2015. 
Sequence variation within the KIV-2 copy number polymorphism of 
the human LPA gene in African, Asian, and European populations. 
PLoS One. 10: e0121582.
 35. Kronenberg, F. 2014. Genetic determination of lipoprotein(a) and 
its association with cardiovascular disease: convenient does not al-
ways mean better. J. Intern. Med. 276: 243–247.
 36. Arai, K., M. M. Luke, M. L. Koschinsky, E. R. Miller, C. R. Pullinger, 
J. L. Witztum, J. P. Kane, and S. Tsimikas. 2010. The I4399M vari-
ant of apolipoprotein(a) is associated with increased oxidized phos-
pholipids on apolipoprotein B-100 particles. Atherosclerosis. 209: 
498–503.
 37. Lee, S-R., A. Prasad, Y-S. Choi, C. Xing, P. Clopton, J. L. Witztum, 
and S. Tsimikas. 2017. LPA gene, ethnicity, and cardiovascular 
events. Circulation. 135: 251–263.
 38. Ogorelkova, M., A. Gruber, and G. Utermann. 1999. Molecular ba-
sis of congenital lp(a) deficiency: a frequent apo(a) “null” mutation 
in Caucasians. Hum. Mol. Genet. 8: 2087–2096.
 39. Surakka, I., M. Horikoshi, R. Mägi, A-P. Sarin, A. Mahajan, V. Lagou, 
L. Marullo, T. Ferreira, B. Miraglio, S. Timonen, et al. 2015. The 
impact of low-frequency and rare variants on lipid levels. Nat. Genet. 
47: 589–597.
 40. van Leeuwen, E. M., A. Sabo, J. C. Bis, J. E. Huffman, A. Manichaikul, 
A. V Smith, M. F. Feitosa, S. Demissie, P. K. Joshi, Q. Duan, et al. 
2016. Meta-analysis of 49,549 individuals imputed with the 1000 
Genomes Project reveals an exonic damaging variant in ANGPTL4 
determining fasting TG levels. J. Med. Genet. 53: 441–449.
 41. Kinpara, K., H. Okada, A. Yoneyama, M. Okubo, and T. Murase. 
2011. Lipoprotein(a)-cholesterol: a significant component of serum 
cholesterol. Clin. Chim. Acta. 412: 1783–1787.
 42. Wade, D. P., L. H. Puckey, B. L. Knight, F. Acquati, A. Mihalich, 
and R. Taramelli. 1997. Characterization of multiple enhancer re-
gions upstream of the apolipoprotein(a) gene. J. Biol. Chem. 272: 
30387–30399.
 43. Puckey, L. H., and B. L. Knight. 2003. Sequence and functional changes 
in a putative enhancer region upstream of the apolipoprotein(a) 
gene. Atherosclerosis. 166: 119–127.
 44. Crawford, D. C., Z. Peng, J-F. Cheng, D. Boffelli, M. Ahearn, D. 
Nguyen, T. Shaffer, Q. Yi, R. J. Livingston, M. J. Rieder, et al. 2008. 
LPA and PLG sequence variation and kringle IV-2 copy number in 
two populations. Hum. Hered. 66: 199–209.
 45. Lanktree, M. B., S. S. Anand, S. Yusuf, and R. A. Hegele; SHARE 
Investigators. 2010. Comprehensive analysis of genomic variation in 
the LPA locus and its relationship to plasma lipoprotein(a) in South 
Asians, Chinese, and European Caucasians. Circ. Cardiovasc. Genet. 3: 
39–46.
 46. Prins, J., F. R. Leus, B. N. Bouma, and H. J. van Rijn. 1999. The 
identification of polymorphisms in the coding region of the apoli-
poprotein (a) gene–association with earlier identified polymorphic 
sites and influence on the lipoprotein (a) concentration. Thromb. 
Haemost. 82: 1709–1717.
 47. Coassin, S., G. Erhart, H. Weissensteiner, M. Eca Guimarães de 
Araújo, C. Lamina, S. Schönherr, L. Forer, M. Haun, J. L. Losso, A. 
Köttgen, et al. A novel but frequent variant in LPA KIV-2 is associ-
ated with a pronounced Lp(a) and cardiovascular risk reduction. 
Eur. Heart J. Epub ahead of print. April 25, 2017; doi:.
 48. Chow, C. K., S. Islam, L. Bautista, Z. Rumboldt, A. Yusufali, C. 
Xie, S. S. Anand, J. C. Engert, S. Rangarajan, and S. Yusuf. 2011. 
Parental history and myocardial infarction risk across the world: the 
INTERHEART Study. J. Am. Coll. Cardiol. 57: 619–627.
 49. Yoshino, S., R. Cilluffo, M. Prasad, P. J. M. Best, E. J. Atkinson, T. 
Aoki, J. M. Cunningham, M. de Andrade, L. O. Lerman, and A. 
Lerman. 2016. Sex-specific genetic variants are associated with coro-
nary endothelial dysfunction. J. Am. Heart Assoc. 5: e002544.
 50. Solomon, T., E. N. Smith, H. Matsui, S. K. Braekkan, INVENT 
Consortium, T. Wilsgaard, I. Njølstad, E. B. Mathiesen, J-B. Hansen, 
and K. A. Frazer. 2016. Associations between common and rare ex-
onic genetic variants and serum levels of 20 cardiovascular-related 
proteins: the Tromsø Study. Circ. Cardiovasc. Genet. 9: 375–383.
 51. Phillips, M. C. 2014. Apolipoprotein E isoforms and lipoprotein me-
tabolism. IUBMB Life. 66: 616–623.
 52. Scanu, A. M., D. Pfaffinger, and C. Edelstein. 1994. Post-prandial 
Lp(a): identification of a triglyceride-rich particle containing apo 
E. Chem. Phys. Lipids. 67–68: 193–198.
 53. Hopkins, P. N., E. A. Brinton, and M. N. Nanjee. 2014. Hyperli-
poproteinemia type 3: the forgotten phenotype. Curr. Atheroscler. 
Rep. 16: 440.
 54. Utermann, G., M. Hees, and A. Steinmetz. 1977. Polymorphism of 
apolipoprotein E and occurrence of dysbetalipoproteinaemia in 
man. Nature. 269: 604–607.
 55. Lindahl, G., F. Mailly, S. Humphries, and M. Seed. 1994. 
Apolipoprotein E phenotype and lipoprotein(a) in familial hyper-
cholesterolaemia: implication for lipoprotein(a) metabolism. Clin. 
Investig. 72: 631–638.
 56. Rader, D. J., W. Cain, L. A. Zech, D. Usher, and H. B. Brewer. 1993. 
Variation in lipoprotein(a) concentrations among individuals with 
the same apolipoprotein (a) isoform is determined by the rate of 
lipoprotein(a) production. J. Clin. Invest. 91: 443–447.
 57. Seimon, T. A., M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. 
T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, 
et al. 2010. Atherogenic lipids and lipoproteins trigger CD36–TLR2-
dependent apoptosis in macrophages undergoing endoplasmic re-
ticulum stress. Cell Metab. 12: 467–482.
 58. Liu, Y., H. Yin, M. Zhao, and Q. Lu. 2014. TLR2 and TLR4 in autoim-
mune diseases: a comprehensive review. Clin. Rev. Allergy Immunol. 
47: 136–147.
 59. Feingold, K. R., A. H. Moser, J. K. Shigenaga, S. M. Patzek, and C. 
Grunfeld. 2008. Inflammation stimulates the expression of PCSK9. 
Biochem. Biophys. Res. Commun. 374: 341–344.
 60. Kamstrup, P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. 
Nordestgaard. 2009. Genetically elevated lipoprotein(a) and in-
creased risk of myocardial infarction. JAMA. 301: 2331–2339.
 61. Emdin, C. A., A. V. Khera, P. Natarajan, D. Klarin, H-H. Won, G. 
M. Peloso, N. O. Stitziel, A. Nomura, S. M. Zekavat, A. G. Bick, 
et al; CHARGE–Heart Failure Consortium and CARDIoGRAM 
Exome Consortium. 2016. Phenotypic characterization of geneti-
cally lowered human lipoprotein(a) levels. J. Am. Coll. Cardiol. 68: 
2761–2772.
 62. Navarese, E. P., M. Kolodziejczak, V. Schulze, P. A. Gurbel, U. 
Tantry, Y. Lin, M. Brockmeyer, D. E. Kandzari, J. M. Kubica, R. B. 
D’Agostino, et al. 2015. Effects of proprotein convertase subtilisin/
kexin type 9 antibodies in adults with hypercholesterolemia: a sys-
tematic review and meta-analysis. Ann. Intern. Med. 163: 40–51.
 63. Viney, N. J., J. C. van Capelleveen, R. S. Geary, S. Xia, J. A. Tami, R. 
Z. Yu, S. M. Marcovina, S. G. Hughes, M. J. Graham, R. M. Crooke, 
et al. 2016. Antisense oligonucleotides targeting apolipoprotein(a) 
in people with raised lipoprotein(a): two randomised, double-blind, 
placebo-controlled, dose-ranging trials. Lancet. 388: 2239–2253.
 at University of Tam












Supplemental Material can be found at:
